2018
DOI: 10.1097/dss.0000000000001468
| View full text |Cite
|
Sign up to set email alerts
|

Abstract: BACKGROUNDThe self-assembling peptide barrier T45K (SAPB-T45K) is an oligopeptide that rapidly forms a biocompatible hemostatic barrier when applied to wounds.OBJECTIVEEvaluate safety and performance of SAPB-T45K in cutaneous surgery.MATERIALS AND METHODSIn this single-blind study, after sequential shave excision of 2 lesions, wounds were randomized (intrapatient) to SAPB-T45K or control treatment. Safety was assessed at treatment, Day 7, and Day 30. Performance was evaluated using time to hemostasis (TTH) and… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
2
0

Year Published

2020
2020
2023
2023

Publication Types

Select...
5

Relationship

0
5

Authors

Journals

citations
Cited by 7 publications
(2 citation statements)
references
References 11 publications
0
2
0
Order By: Relevance
“…Similarly, a chiral version of EAK16 (Sciobio) is used to treat severe bedsore and chronic diabetic ulcers, and to promote wound healing 216 . Other peptide-based systems that have been tested in clinical trials are available on the market, including the mineralizing peptide P11-4 (Curolox) for the treatment of dental caries 217 , and T45K (AC5) 218 for haemostatic control in patients undergoing antiplatelet therapy. Of note, clinical trials investigating peptide hydrogels are currently mainly focused on the treatment of dental caries, tooth diseases, haemorrhages and skin diseases.…”
Section: Peptide Hydrogels On the Marketmentioning
confidence: 99%
“…Similarly, a chiral version of EAK16 (Sciobio) is used to treat severe bedsore and chronic diabetic ulcers, and to promote wound healing 216 . Other peptide-based systems that have been tested in clinical trials are available on the market, including the mineralizing peptide P11-4 (Curolox) for the treatment of dental caries 217 , and T45K (AC5) 218 for haemostatic control in patients undergoing antiplatelet therapy. Of note, clinical trials investigating peptide hydrogels are currently mainly focused on the treatment of dental caries, tooth diseases, haemorrhages and skin diseases.…”
Section: Peptide Hydrogels On the Marketmentioning
confidence: 99%
“…Later on, in a prospective, randomized clinical trial, the same SAP was demonstrated to be effective, and significantly better than standard treatments, in regenerating decayed enamel, favoring the formation of novel hydroxyapatite at the bottom of early carious lesions 42 . Recently, another SAP, named T45K, was tested for safety and efficacy as hemostat solution for small-size skin wounds in a blind clinical trial 43 . Authors showed that with T45K, if compared to control treatment, a faster time to hemostasis and superior wound healing could be achieved also in patients undergoing antiplatelet therapy.…”
Section: Other Sap Scaffolds In Clinical Trialsmentioning
confidence: 99%